Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.33 |
| ▸ | POLQ | O75417 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 2/20 | 0.31 |
| ▸ | LCK | P06239 | 1/20 | 0.30 |
| ▸ | KDR | P35968 | 1/20 | 0.30 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23059628 | 0.93 | GPBAR1 (0.34) | GPBAR1POLQPTGESLCKKDR | |
| SCHEMBL25085560 | 0.93 | GPBAR1 (0.35) | ARGPBAR1PTGES | |
| SCHEMBL25085598 | 0.92 | AR (0.32) | ARGPBAR1 | |
| SCHEMBL25085569 | 0.92 | AR (0.32) | ARGPBAR1 | |
| SCHEMBL23059630 | 0.91 | GPBAR1 (0.33) | ARGPBAR1POLQPTGES | |
| SCHEMBL23059716 | 0.91 | GPBAR1 (0.32) | ARGPBAR1 | |
| SCHEMBL23641916 | 0.90 | GPBAR1 (0.38) | GPBAR1POLQ | |
| SCHEMBL24914495 | 0.90 | PTGES (0.31) | PTGESLCKKDRMAPK14 | |
| SCHEMBL23059690 | 0.89 | AR (0.36) | ARGPBAR1POLQPTGESLCK | |
| SCHEMBL30266820 | 0.89 | AR (0.36) | ARGPBAR1POLQPTGESLCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | Metisa Biotechnology Co., Ltd (CN) | 2023-03-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230065544-A1 | ISOPHTHALAMINDE COMPOUND AND USE THEREOF | DDT, INMT, CYP2B6 | AR 2559/4885GPBAR1 952/4885POLQ 4824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.